Patents Assigned to University of Zurich
-
Patent number: 9580493Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: June 22, 2012Date of Patent: February 28, 2017Assignees: Biogen International Neuroscience GmbH, University of ZürichInventors: Andreas Weihofen, Jan Grimm, Christoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
-
Patent number: 9568366Abstract: A multidimensional spectrometer encodes frequency information into laser pulses so that a frequency insensitive detector may be used to collect data for a multi-dimensional spectrograph only from intensity information and knowledge of a modulation providing the encoding. In one embodiment the frequency encoding may be done by a conventional interferometer greatly simplifying construction of the spectrometer.Type: GrantFiled: May 15, 2015Date of Patent: February 14, 2017Assignees: Wisconsin Alumni Research Foundation, University of ZurichInventors: Martin Thomas Zanni, Peter Hamm, Jan Helbing
-
Patent number: 9512156Abstract: The present invention relates to new rhenium compounds of formula (I) with medical utility, corresponding pharmaceutical compositions as well as medical uses thereof.Type: GrantFiled: March 4, 2011Date of Patent: December 6, 2016Assignee: UNIVERSITY OF ZURICHInventors: Fabio Zobi, Roger Alberto, Lukas Kromer
-
Patent number: 9512202Abstract: The invention relates to a method for isolating a polypeptide reactive to influenza A hemagglutinin, comprising the steps of preparing a library of nucleic acid sequences, wherein each member of said library is attached to a polypeptide sequence encoded thereby, selecting members of said library by contacting the members with a panning antigen, wherein the panning antigen comprises a hemagglutinin stem region polypeptide sequence, subsequently removing members unreactive to the panning antigen, and selecting a member of said library by determining its binding to at least 5 influenza A hemagglutinin subtypes of subtype group 1 and 2. The invention further relates to polypeptides, particularly antibodies, obtainable by this method, that neutralize at least five influenza A subtypes of subtype group 1 and 2, to vaccines and uses thereof.Type: GrantFiled: August 27, 2012Date of Patent: December 6, 2016Assignee: UNIVERSITY OF ZURICHInventors: Lars Hangartner, Arkadiusz Wyrzucki
-
Publication number: 20160289310Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.Type: ApplicationFiled: March 10, 2016Publication date: October 6, 2016Applicant: University of ZurichInventors: Roger Nitsch, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
-
Patent number: 9447142Abstract: The present invention relates to a filamentous phage display method wherein the polypeptides of interest displayed on the phage particle are cotranslationally translocated across the cytoplasmic membrane of Gram-negative bacteria based on the signal recognition particle pathway. This method is particularly suitable for polypeptides, which are known to be difficult to display on phages, and for proteins of cDNA libraries and other combinatorial libraries, in particular when derived from very fast folding, stable protein scaffolds. The invention further relates to phage or phagemid vectors useful in the method comprising a gene construct coding for a fusion polypeptide comprising the polypeptide to be displayed on the phage particle and an N-terminal signal sequence promoting cotranslational translocation.Type: GrantFiled: August 26, 2014Date of Patent: September 20, 2016Assignee: University of ZurichInventors: Daniel Steiner, Patrik Forrer, Michael T. Stumpp, Andreas Pluckthun
-
Patent number: 9434944Abstract: A miR-323-3p inhibitor is provided for the prevention or therapy of rheumatoid arthritis, comprising a sequence capable of forming a hybrid to miR-323-3p as an oligonucleotide or a vector from which such oligonucleotide is transcribed, or as a miRNA decoy or sponge.Type: GrantFiled: August 31, 2012Date of Patent: September 6, 2016Assignee: UNIVERSITY OF ZURICHInventors: Steffen Gay, Mary Connolly, Caroline Ospelt
-
Publication number: 20160244515Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: January 25, 2016Publication date: August 25, 2016Applicants: Biogen International Neuroscience GmbH, University of ZurichInventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
-
Patent number: 9365629Abstract: The invention relates to collections of target-specific designed binding proteins based on armadillo repeat proteins, and to a method of generating them. Designed armadillo repeat proteins are based on consensus sequences of single armadillo repeat units. These repeat proteins can be used as scaffolds for peptide recognition. Such a scaffold provides a binding mode that is in principle the same for every small recognizable unit, e.g. an amino acid or dipeptide, allowing a precise and modular recognition of a peptide in extended conformation. The method allows to generate a series of modules recognizing these simple units, and to combine such building blocks to create a binding site for any desired peptide target without performing additional selections.Type: GrantFiled: September 23, 2008Date of Patent: June 14, 2016Assignee: University of ZurichInventors: Fabio Parmeggiani, Riccardo Pellarin, Anders Peter Larsen, Gautham Varadamsetty, Michael Tobias Stumpp, Andreas Plückthun
-
Patent number: 9351742Abstract: A drill guide includes a first bone plate that extends along a first middle plane, and a second bone plate that extends along a second middle plane. The drill guide further includes a first articulation and a second articulation that is connected to the first articulation. The first and second articulations are arranged between the first and the second bone plate. Each of the first and second articulations is releasably lockable.Type: GrantFiled: November 17, 2014Date of Patent: May 31, 2016Assignee: The University of ZurichInventors: Andreas Appenzeller, Ladislav Nagy, Andreas Schweizer, Daniel Fluri
-
Patent number: 9351820Abstract: A device for repair surgery of cylindrical organs, particularly ruptured tendons, is configured as a tubular sheath (T) made of a biocompatible and biodegradable polymer. The tubular sheath comprises an elastic fiber mesh formed by electrospinning of said polymer and has an inner wall surface and an outer wall surface substantially parallel thereto. One of said wall surfaces is comparatively rough (WR) and the other one of said wall surfaces is comparatively smooth (WS), with the tubular sheath having a Young elasticity modulus of about 2 to about 5 MPa and an elongation at break of about 50 to about 1,000%. Preferably, the polymer is a biodegradable polyester urethane block copolymer with poly-hydroxy-butyrate as a hard 10 segment and ?-caprolactone as a soft segment.Type: GrantFiled: August 26, 2012Date of Patent: May 31, 2016Assignee: University of ZurichInventor: Johanna Buschmann
-
Patent number: 9317127Abstract: A motion recognizing apparatus and method are provided. According to an aspect, a motion recognizing apparatus may include: an optical sensor configured to sense at least a portion of a subject where a motion occurs and to output one or more events in response thereto; a motion tracing unit configured to trace a motion locus of the portion where the motion occurs based on the one or more outputted events; and a motion pattern determining unit configured to determine a motion pattern of the portion where the motion occurs based on the traced motion locus.Type: GrantFiled: March 6, 2014Date of Patent: April 19, 2016Assignees: Samsung Electronics Co., Ltd., University of ZurichInventors: Jun Haeng Lee, Tobi Delbruck, Hyunsurk Ryu, Keun Joo Park, Chang Woo Shin
-
Patent number: 9296678Abstract: The present invention relates to compounds according to formula (I) for medical use. The compounds are particularly suitable for the treatment and/or prevention of a medical condition involving hypoxic, anoxic and/or inflamed mammalian tissue. Furthermore, the invention relates to the use of said compounds for preparing a medicament and to pharmaceutical preparations comprising such compounds. The invention also relates to methods of treating or protecting patients having or being prone to develop a medical condition involving hypoxic, anoxic and/or inflamed mammalian tissue, the methods comprising administration of a therapeutically effective amount of such compounds.Type: GrantFiled: December 11, 2013Date of Patent: March 29, 2016Assignees: UNIVERSITY OF ZURICH, ETH ZURICHInventors: Ludwig K. Limbach, Inge K. Herrmann, Beatrice Beck-Schimmer, Wendelin J. Stark, Martin Urner
-
Patent number: 9295857Abstract: A method of delivering a radioactive liquid includes, performing an initialization, including; extracting at least a first amount of a radioactive liquid from a source of radioactive liquid, measuring a radioactivity level for the first amount of radioactive liquid, and performing a calibration phase. The calibration phase includes, extracting a second amount of radioactive liquid from the source of radioactive liquid wherein the second amount is calculated based on the radioactivity level of the first amount to provide a total dose of radioactive liquid having a predetermined radioactivity level, and delivering the total dose and performing at least one more calibration and delivery phases.Type: GrantFiled: October 3, 2014Date of Patent: March 29, 2016Assignee: University of ZurichInventors: Alfred Buck, Bruno Weber
-
Patent number: 9283271Abstract: Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: December 19, 2011Date of Patent: March 15, 2016Assignees: Neurimmune Holding AG, University of ZurichInventors: Fabio Montrasio, Maria Grazia Barenco Montrasio, Jan Grimm, Roger Nitsch, Christoph Hock, Marcel Maier
-
Patent number: 9271993Abstract: Novel pharmacological treatment of bacterial infectious diseases in humans by use of apramycin of formula (I) or apramycin derivatives having significantly low toxicity.Type: GrantFiled: September 12, 2011Date of Patent: March 1, 2016Assignees: UNIVERSITY OF ZURICH, ETH ZURICHInventors: Erik Boettger, Andrea Vasella
-
Patent number: 9273126Abstract: The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerization of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.Type: GrantFiled: November 2, 2012Date of Patent: March 1, 2016Assignees: Delenex Therapeutics AG, University of ZurichInventors: Stefan Ewert, Adrian Auf Der Maur, Susann Cattepoel, Roger Nitsch
-
Patent number: 9259484Abstract: The present invention relates to methods for preventing or treating head and neck squamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using Vb4-845, which is a recombinant immunotoxin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of Pseudomonas exotoxin A. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer.Type: GrantFiled: August 29, 2013Date of Patent: February 16, 2016Assignee: UNIVERSITY OF ZURICHInventors: Uwe Zangemeister-Wittke, Claudio Di Paolo, Dominique Christine Tschudi, Nicholas Ronald Glover, Dimitri Peter Fitsialos
-
Patent number: 9174991Abstract: The present invention relates to a new polymorphic or crystalline form of Pemetrexed Disodium, processes for its preparation and its use, in particular for the preparation of medicaments.Type: GrantFiled: November 24, 2010Date of Patent: November 3, 2015Assignees: Azad Pharmaceutical Ingredients AG, University of ZurichInventors: Uwe Jens Albrecht, Hannes Helmboldt, Vsevolod Valerievich Nikolaev
-
Publication number: 20150252102Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: November 4, 2014Publication date: September 10, 2015Applicants: UNIVERSITY OF ZURICH, BIOGEN IDEC INTERNATIONAL NEUROSCIENCE GMBHInventors: ROGER NITSCH, FENG CHEN, JAN GRIMM, JEAN-LUC BAERISWYL, CHRISTOPH HOCK